Necessity of screening patients with stenting for acute coronary syndrome by CYP2C19 polymorphism
https://doi.org/10.25789/YMJ.2018.64.31
Abstract
The relevance of this article is due to the fact that cardiovascular diseases are currently the leading cause of death and disability worldwide. The leading role in the structure of mortality from cardiovascular diseases belongs to coronary heart disease. Ischemic heart disease (IHD) is a chronic disease that develops with insufficient oxygen supply to the myocardium. The main cause (more than 90% of cases) of insufficient intake of oxygen is the formation of atherosclerotic plaques in the lumen of the coronary arteries, the arteries of the blood supplying the heart muscle (myocardium). One of the main drugs for antiplatelet therapy in cardiology is clopidogrel, the use of which can reduce the incidence of thrombotic complications. Clopidogrel is the most famous member of the thienopyridine group. Clopidogrel remains the main drug for antiplatelet therapy in patients who received stenting of the coronary vessels for acute coronary syndrome. The rationale and design of the observational study aimed at testing the hypothesis that the high frequency of the genetic polymorphism of cytochrome CYP2C19*2 is associated with coronary stent thrombosis is presented.
About the Authors
I. T. Terentiev
Federal State Budgetary Institution “Yakut science center of complex medical problems”
Russian Federation
Russian Federation
Terentiev Ivan Titovich - doctor cardiologist, junior researcher of the laboratory of heritable pathology
677010, Republic of Sakha (Yakutia), Yakutsk, Sergelyahskoe St, 4
+7 (924) 173 15 05
M. A. Varlamova
Federal State Budgetary Institution “Yakut science center of complex medical problems”
Russian Federation
Russian Federation
Varlamova Marina Alekseevna –researcher of the laboratory of heritable pathology
677010, Republic of Sakha (Yakutia), Yakutsk, Sergelyahskoe St, 4
8 (914) 298 87 60
N. I. Pavlova
Federal State Budgetary Institution “Yakut science center of complex medical problems”
Russian Federation
Russian Federation
Pavlova Nadezhda Ivanovna – cbs, temporary acting chief scientific officer - head of the laboratory of heritable pathology
677010, Republic of Sakha (Yakutia), Yakutsk, Sergelyahskoe St, 4
+7 (914) 289 39 36
A. T. D’yakonova
Federal State Budgetary Institution “Yakut science center of complex medical problems”
Russian Federation
Russian Federation
D’yakonova Aleksandra Timofeevna – Junior researcher of the laboratory of heritable pathology
677010, Republic of Sakha (Yakutia), Yakutsk, Sergelyahskoe St, 4
8 (914) 238 68 93
N. A. Solov’eva
Federal State Budgetary Institution “Yakut science center of complex medical problems”
Russian Federation
Russian Federation
Solov’eva Natal’ya Alekseevna – cms, temporary acting chief scientific officer - head of the Laboratory of Population Genetics
677010, Republic of Sakha (Yakutia), Yakutsk, Sergelyahskoe St, 4
8 (924) 171 34 89
S. K. Kononova
Federal State Budgetary Institution “Yakut science center of complex medical problems”
Russian Federation
Russian Federation
Kononova Sardana Kononovna - senior researcher of the laboratory of molecular genetics
677010, Republic of Sakha (Yakutia), Yakutsk, Sergelyahskoe St, 4
8 (924) 166 06 77
Kh. A. Kurtanov
Federal State Budgetary Institution “Yakut science center of complex medical problems”
Russian Federation
Russian Federation
Kurtanov Khariton Alekseevich – cms, Chief Scientific Officer - Head of the Department of Molecular Genetics
677010, Republic of Sakha (Yakutia), Yakutsk, Sergelyahskoe St, 4
+7 (914) 106 00 30
References
1. Association of genes encoding hemostasis proteins, with parameters of peripheral hemostasis and predisposition to atherothrombosis in patients with cardiovascular diseases / G.I. Lifshitz, S.T. Danilkina, E.V. Guskova, E.N. Voronina, M.L. Filipenko // Cardiovascular Therapy and Prevention 2011, 4: 90-6. https://doi.org/10.15829/1728-8800-2016-3-63-68.
2. Barysheva V.O. Analysis of the relationship between the results of pharmacogenetic testing for the determination of resistance to clopidogrel and stent thrombosis in patients / V.O. Barysheva, G.G., Ketova // Pharmacogenetics and pharmacogenomics. – 2017. – №2. – C.7-8. http://www.pharmacogenetics-pharmacogenomics.ru/item/ analiz-svyazi-rezultatov-farmakogeneticheskogotestirovaniya-dlya-opredeleniya-rezistentnosti-kklopidogrelu-i-tromboza-stenta-u-patsientov.
3. Bokeria L.A. Guide to X-ray Endovascular Surgery of the Heart and Vessels / L.A. Bokeria, B.G. Alekyan. – M.: NTSSSH im. A.N. Bakuleva Russian Academy of Medical Sciences. – 2013. – T.3. https://elibrary.ru/item.asp?id=19096971.
4. The influence of genetic polyphorphism of the gene CYP2C19 on the choice of effective antiplatelet therapy after the operation of coronary artery stenting / Z.F. Kudzoeva, L.A. Bokeria, O.L. Bokeria, A.K. Koasari // A.N. Bakulev FGBU NTSSSH RAMS. https://racvs.ru/events/archive/xviii_ezhegodnaya_sessiya_nauchnogo_tsentra_serdechnososudistoy_khirurgii_im_an_bakuleva_ramn_s_vser/vliyanie_geneticheskogo_poliforfizma_gena_CYP2C19_na_vybor_effektivnoy_antiagregantnoy_terapii_posle/.
5. Influence of the metabolic activity of the CYP3A4 isoenzyme and polymorphic markers of the CYP2C19 gene on the antiplatelet effect of clopidogrel in patients with acute coronary syndrome who underwent percutaneous coronary intervention / К.В. Mirzaev, R.E. Kazakov, V.V. Smirnov [et al.] // Rational Pharmacotherapy in Cardiology. – 2015. T. 11. № 4. S. 344-354. https://doi.org/10.20996/1819-6446-2015-11-4-344-354.
6. Генетические, патофизиологические и клинические аспекты антиагрегантной терапии / Е.А. Апарцин, Г. И. Лифшиц, А.А. Слепухина [и др.] // Фармакогенетика и фармакогеномика. – 2015. – №2. – С. 12-19. http://www. pharmacogenetics-pharmacogenomics.ru/item/geneticheskie-patofiziologicheskie-i-klinicheskieaspekty-antiagregantnoj-terapii.
7. Clinical significance of CYP2C19 gene polymorphism in patients with acute coronary syndrome with ST segment elevation (data from the register of acute coronary syndrome in Kemerovo) / A.M. Kochergina, V.V. Kashtalap, L.A. Gordeeva [et al.] // Molecular Medicine. – 2017.– T.5, №4. – С.33-36. https://molmedjournal.ru/ru/molecmed-2017-04-06.
8. Kurcheva N.P. Multifactorial algorithm for predicting the antiplatelet effect of clopidogrel, as a potential way to increase the efficacy and safety of antiplatelet therapy / N.P. Kurcheva, K.B. Mirzaev, D.A. Sychev // Pharmacogenetics and pharmacogenomics. – 2015. – №2. – P.29-32. http://www.pharmacogeneticspharmacogenomics.ru/articles/item/mnogofaktornyj-algoritm-prognozirovaniyaantiagregantnogo-dejstviya-klopidogrela-kakpotentsialnyj-sposob-povysheniya-effektivnosti-ibezopasnosti-antiagregantnoj-terapii.
9. Lifshits G.I. Prospective multicenter observational study Protocol: personalized therapy with clopidogrel in stenting for acute coronary syndrome with genetic polymorphisms taken into account / G.I. Lifshits, K.A. Aparzin // Qualitative clinical practice. – 2015. - №1.- Р.78-86. https://www.clinvest.ru/jour/article/view/
10. Martsevich S.Yu. Antiaggregant therapy in patients with a high risk of thrombotic complications: the problem of efficacy, safety and adherence / S.Yu. Martsevich, N.P. Kutishenko, M.L. Ginzburg // Clinician. – 2001. – № 2. – P.72-79. https://doi.org/10.17650/1818-8338-2011-2-72-79.
11. Polymorphism of the CYP2C19 gene in patients with myocardial infarction using clopidogrel /A.S. Galyavich, D.D. Valeeva, R.Sh. Minnetdinov [et al.] // Cardiology. – 2012. № 4. P. 20-24. https://lib.medvestnik.ru/articles/Polimorfizm-gena-CYP2C19-u-bolnyh-infarktommiokarda-primenyaushih-klopidogrel.html.
12. Predictors of stent thrombosis in patients with acute coronary syndrome with ST-segment elevation undergoing a primary procedure on the coronary artery / S.A. Burns, E.A. Schmidt, E.S. Kiprina [et al.] // Cardiology.-2011. – №51. – №4. – P.10-15. https://lib.medvestnik.ru/articles/Prediktory-tromboza-stenta-u-bolnyh-s-ostrym-koronarnym-sindromom-s-podemom-segmentaST-podvergshihsya-pervichnoi-procedure-nakoronarnoi-arterii.html.
13. Solodun M.V. Pharmacotherapy with myocardial infarction: the contribution of genetic factors / M.V. Solodun // Russian Cardiology Journal. – 2016. – № 3 (131). https://doi.org/10.15829/1560-4071-2016-3-111-116.
14. Chernov A.A. The first meta-analysis of domestic pharmacogenetic studies of clopidogrel / A.A. Chernov, K.B. Mirzaev, D.A. Sychev // Pharmacogenetics and pharmacogenomics. – 2015. – №2. – P.19-23. http://pharmacogenetics-pharmacogenomics.ru/item/42.
15. CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular EventsA Systematic Review and Meta-analysis / M.V. Holmes, P. Perel, T. Shan, D. Aroon, P. Juan. // JAMA. 2011; 306(24):2704-2714. https://doi.org/10.1001/jama.2011.1880.
16. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study / J.Collet, J.Hulot, A. Pena A. et al. Lancet 2009. 373(9660):309-17. DOI: 10.1016/S0140-6736(08)61845-0.
17. Cytochrome P-450 Polymorphisms and Response to Clopidogrel / Mega J., Close S., Wiviott S. [et al.] //N Engl J Med 2009.360(4):354- 62. DOI: 10.1056/NEJMoa0809171.
18. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention / D. Aradi, R.F. Storey,A. Komócsi, D. Trenk, D. Gulba, R.G. Kisset al. // Eur Heart J 2014, 35(4): 209-15. DOI:10.1093/eurheartj/eht375.
19. Genetic determinants of response to clopidogrel and cardiovascular events / T. Simon, C. Verstuyft, M. Mary-Krause et al.. N Engl J Med 2009.360(4):363-75. DOI:10.1056/NEJMoa0808227.
20. Guidelines on myocardial revascularization / W. Wijns, P. Kolh, N. Danchin et al. // Eur Heart J. 2010. Vol. 31. № 20. P. 2501–2555. doi:10.1093/eurheartj/ehq277.
21. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis / J.L. Mega, Т. Simon, J.P. Collet, J.L. Anderson, E.M. Antman, К. Bliden et al. // JAMA 2010, 304(16): 1821-30. DOI: 10.1001/jama.2010.1543.
22. Relationship of CYP2C19*2 and CYP2C19*3 gene polymorphism with clopidogrel response variability and recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention / Y. Liu, N Liu, W Li, et al. // Pharmacology. 2013; 91 (3-4): 165- 72. DOI: 10.1159/000346736.
23. The CURRENT-OASIS 7 Investigators. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes // N Engl J Med 2010,363(10): 930-42. DOI: 10.1056/NEJMoa0909475.
24. The Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study: Variation in Platelet Response to Clopidogrel and Aspirin / L.M. Bozzi, B.D. Mitchell, J.P. Lewis, et al. // Current vascular pharmacology. 2016; 14(1):116-124. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842002/.
25. Standard– vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary InterventionThe GRAVITAS Randomized Trial / MJ Price, PB Berger, PS Teirstein, et al. // JAMA.2011;305(11):1097–1105. doi:10.1001/jama.2011.290.
26. Use of clopidogrel with or without aspirin in patients taking oralanticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial / W.J.M.Dewilde, T.Oirbans, F.W.A.Verheugt, J.C.Kelder, B.J.G.L. De Smet, J-P. Herrman et al. // Lancet 2013, 381(9872): 1107-15. DOI: 10.1016/S0140-6736(12)62177-1.
Review
For citations:
Terentiev I.T., Varlamova M.A., Pavlova N.I., D’yakonova A.T., Solov’eva N.A., Kononova S.K., Kurtanov Kh.A. Necessity of screening patients with stenting for acute coronary syndrome by CYP2C19 polymorphism. Yakut Medical Journal. 2018;(4):102-105. https://doi.org/10.25789/YMJ.2018.64.31
Views:
4
Email this article 